PDSB
PDS Biotechnology Delivers Strong Q4 2025 Results, Advancing Clinical Programs with Promising Treatments for HPV-16 Positive Head and Neck Cancer and Metastatic Castration-Resistant Prostate Cancer
PDS Biotechnology Corporation has reported a successful fourth quarter of 2025, marked by significant progress across its clinical programs. The company's management team, comprising Dr. Frank Bedu-Addo (Chief Executive Officer), Dr. Kirk Shepherd (Chief Medical Officer), and Lars Boesgaard (Chief Financial Officer), provided an update on the company&